SCHEMBL714109

SCHEMBL714109

Cc1nc(N)nc(N[C@@H](C)c2cc3c(F)ccc(C)c3nc2N2CCNC(=O)C2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 2/20 0.37
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
IDH1 O75874 7/20 0.33
PRKCH P24723 1/20 0.33
PRKCE Q02156 1/20 0.33
KRAS P01116 1/20 0.32
HRH4 Q9H3N8 1/20 0.31
DPP4 P27487 1/20 0.31
PRMT5 O14744 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
CCND3 P30281 1/20 0.31
CDK9 P50750 1/20 0.31
CDK6 Q00534 1/20 0.31
GRIA1 P42261 1/20 0.31
CACNG2 Q9Y698 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714110 1.00 SOS1 (0.37) SOS1JAK2JAK1TYK2JAK3
SCHEMBL717880 0.87 SOS1 (0.39) SOS1JAK2JAK1TYK2JAK3
SCHEMBL717881 0.87 SOS1 (0.39) SOS1JAK2JAK1TYK2JAK3
SCHEMBL716805 0.85 PIK3CD (0.40) SOS1IDH1PRKCHPRKCEKRAS
SCHEMBL17530773 0.83 SOS1 (0.34) SOS1JAK2JAK1TYK2JAK3
SCHEMBL717871 0.83 PRKCH (0.38) SOS1PRKCHPRKCEDPP4PRMT5
SCHEMBL717872 0.83 PRKCH (0.38) SOS1PRKCHPRKCEDPP4PRMT5
SCHEMBL715908 0.83 SOS1 (0.36) SOS1PRKCHPRKCEDPP4PRMT5
SCHEMBL713509 0.81 PIK3CD (0.38) SOS1IDH1PRKCHPRKCEKRAS
SCHEMBL713510 0.81 PIK3CD (0.38) SOS1IDH1PRKCHPRKCEKRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 SOS1 1414/4885JAK2 51/4885JAK1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.